Department of Orthopedic Surgery, Washington University in St. Louis, St. Louis, Missouri, USA.
Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, Connecticut, USA.
J Orthop Res. 2021 Feb;39(2):402-414. doi: 10.1002/jor.24965. Epub 2021 Jan 13.
Infection is a devastating complication following an open fracture. We investigated whether local rifampin-loaded hydrogel can combat infection and improve healing in a murine model of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. A transverse fracture was made at the tibia midshaft of C57BL/6J mice aged 10-12 weeks and stabilized with an intramedullary pin. A total of 1 × 10 colony-forming units (CFU) of MRSA was inoculated. A collagen-based hydrogel containing low-dose (60 μg) and high-dose (300 μg) rifampin was applied before closure. Postoperative treatment response was assessed through bacterial CFU counts from tissue and hardware, tibial radiographs and microcomputed tomography (μCT), immunohistochemistry, and histological analyses. All untreated MRSA-infected fractures progressed to nonunion by 28 days with profuse MRSA colonization. Infected fractures demonstrated decreased soft callus formation on safranin O stain compared to controls. Areas of dense interleukin-1β stain were associated with poor callus formation. High-dose rifampin hydrogels reduced the average MRSA load in tissue (p < 0.0001) and implants (p = 0.041). Low-dose rifampin hydrogels reduced tissue bacterial load by 50% (p = 0.021). Among sterile models, 88% achieved union compared to 0% of those infected. Mean radiographic union scale in tibia scores improved from 6 to 8.7 with high-dose rifampin hydrogel (p = 0.024) and to 10 with combination local/systemic rifampin therapy (p < 0.0001). μCT demonstrated reactive bone formation in MRSA infection. Histology demonstrated restored fracture healing with bacterial elimination. Rifampin-loaded hydrogels suppressed osteomyelitis, prevented implant colonization, and improved healing. Systemic rifampin was more effective at eliminating infection and improving fracture healing. Further investigation into rifampin-loaded hydrogels is required to correlate these findings with clinical efficacy.
感染是开放性骨折后一种毁灭性的并发症。我们研究了局部利福平载水凝胶是否可以在耐甲氧西林金黄色葡萄球菌(MRSA)骨髓炎的小鼠模型中对抗感染并改善愈合。在 10-12 周龄 C57BL/6J 小鼠的胫骨中段制造横断骨折,并通过髓内针固定。共接种 1×10 个 CFU 的 MRSA。在闭合前应用含有低剂量(60μg)和高剂量(300μg)利福平的胶原基水凝胶。通过组织和硬件、胫骨 X 光片和微计算机断层扫描(μCT)、免疫组织化学和组织学分析评估术后治疗反应。所有未经治疗的 MRSA 感染性骨折在 28 天内均进展为骨不连,并伴有大量 MRSA 定植。与对照组相比,感染性骨折在番红 O 染色上的软愈伤组织形成减少。密集的白细胞介素-1β染色区域与愈伤组织形成不良有关。高剂量利福平水凝胶减少了组织(p<0.0001)和植入物(p=0.041)中的平均 MRSA 负荷。低剂量利福平水凝胶使组织细菌负荷减少 50%(p=0.021)。在无菌模型中,88%的患者达到愈合,而感染患者为 0%。高剂量利福平水凝胶使胫骨评分的平均放射学愈合评分从 6 提高到 8.7(p=0.024),联合局部/全身利福平治疗提高到 10(p<0.0001)。μCT 显示 MRSA 感染时出现反应性骨形成。组织学显示在消除细菌的同时恢复骨折愈合。利福平载水凝胶抑制骨髓炎、防止植入物定植并改善愈合。全身利福平在消除感染和改善骨折愈合方面更有效。需要进一步研究利福平载水凝胶,将这些发现与临床疗效相关联。